# Bausch Health Companies Inc.: overview

BHC · NYSE · CIK 885590 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bhc.md) · [Financials](/companies/bhc/financials.md) · [Filings](/companies/bhc/filings.md) · [Insiders](/companies/bhc/insiders.md)

Latest reported revenue: [$2.85bn](/filings/0000885590-26-000107.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000885590-26-000107).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,510](/filings/0000885590-25-000051.md) | [2,559 d](/filings/0000885590-26-000023.md) | [2,259](/filings/0000885590-26-000053.md) | [2,530](/filings/0000885590-26-000107.md) | [2,681](/filings/0000885590-25-000051.md) | [2,796 d](/filings/0000885590-26-000023.md) | [2,524](/filings/0000885590-26-000053.md) | [2,852](/filings/0000885590-26-000107.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [12.7%](/filings/0000885590-25-000051.md) | [21.8% d](/filings/0000885590-26-000023.md) | [12.2%](/filings/0000885590-26-000053.md) | [17.5%](/filings/0000885590-26-000107.md) | [23.1%](/filings/0000885590-25-000051.md) | [17.0% d](/filings/0000885590-26-000023.md) | [(37.6%)](/filings/0000885590-26-000053.md) | [25.9%](/filings/0000885590-26-000107.md) |
| Net margin | % | [(3.4%)](/filings/0000885590-25-000051.md) | [3.6% d](/filings/0000885590-26-000023.md) | [(2.6%)](/filings/0000885590-26-000053.md) | [5.8%](/filings/0000885590-26-000107.md) | [6.7%](/filings/0000885590-25-000051.md) | [(4.0%) d](/filings/0000885590-26-000023.md) | [(56.4%)](/filings/0000885590-26-000053.md) | [9.0%](/filings/0000885590-26-000107.md) |
| Diluted EPS | $ per share | [(0.23)](/filings/0000885590-25-000051.md) | not reported | [(0.16)](/filings/0000885590-26-000053.md) | [0.40](/filings/0000885590-26-000107.md) | [0.48](/filings/0000885590-25-000051.md) | not reported | [(3.82)](/filings/0000885590-26-000053.md) | [0.68](/filings/0000885590-26-000107.md) |
| Free cash flow | $m | [334 d](/filings/0000885590-25-000051.md) | [495 d](/filings/0000885590-26-000023.md) | [96.0](/filings/0000885590-26-000053.md) | [190 d](/filings/0000885590-26-000107.md) | [314 d](/filings/0000885590-25-000051.md) | [403 d](/filings/0000885590-26-000023.md) | [121](/filings/0000885590-26-000053.md) | [593 d](/filings/0000885590-26-000107.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [8.4](/filings/0000885590-24-000011.md) | [8.1](/filings/0000885590-25-000007.md) | [8.8](/filings/0000885590-26-000023.md) | [9.6](/filings/0000885590-26-000023.md) | [10.3](/filings/0000885590-26-000023.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [5.3%](/filings/0000885590-24-000011.md) | [5.6%](/filings/0000885590-25-000007.md) | [11.0%](/filings/0000885590-26-000023.md) | [16.1%](/filings/0000885590-26-000023.md) | [17.7%](/filings/0000885590-26-000023.md) |
| Net margin | % | [(11.2%)](/filings/0000885590-24-000011.md) | [(2.8%)](/filings/0000885590-25-000007.md) | [(6.8%)](/filings/0000885590-26-000023.md) | [(0.5%)](/filings/0000885590-26-000023.md) | [1.5%](/filings/0000885590-26-000023.md) |
| Diluted EPS | $ per share | [(2.64)](/filings/0000885590-24-000011.md) | [(0.62)](/filings/0000885590-25-000007.md) | [(1.62)](/filings/0000885590-26-000023.md) | [(0.13)](/filings/0000885590-26-000023.md) | [0.42](/filings/0000885590-26-000023.md) |
| Free cash flow | $bn | [1.2](/filings/0000885590-24-000011.md) | [(0.9)](/filings/0000885590-25-000007.md) | [0.8](/filings/0000885590-26-000023.md) | [1.3](/filings/0000885590-26-000023.md) | [1.0](/filings/0000885590-26-000023.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bhc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [PAULSON & CO. INC.](/funds/1035674.md) | 2026-06-30 | $361.2m | 73,255,869 |  | Unchanged |
| [GOLDENTREE ASSET MANAGEMENT LP](/funds/1278951.md) | 2026-06-30 | $170.7m | 34,665,731 |  | Unchanged |
| [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $53.4m | 10,832,582 |  | Reduced −530,916 |
| [HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND](/funds/1535845.md) | 2026-06-30 | $39.4m | 8,000,000 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $36.8m | 7,465,468 |  | Added +61,709 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $33.2m | 4,803,485 |  | Added +574,614 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $30.7m | 6,225,131 |  | Added +1,017,165 |
| [MFN Partners Management, LP](/funds/1732811.md) | 2026-06-30 | $29.6m | 6,000,000 |  | Unchanged |
| [Kohlberg Kravis Roberts & Co. L.P.](/funds/1399770.md) | 2026-06-30 | $25.8m | 5,235,000 |  | Unchanged |
| [ING GROEP NV](/funds/1039765.md) | 2026-06-30 | $24.6m | 5,000,000 |  | Unchanged |

## Recent filings

[All 2,156 filings](/companies/bhc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-30 | 20:11 ET | [10-Q](/filings/0000885590-26-000107.md) | Quarterly report, period 2026-06-30 | 0000885590-26-000107 |
| 2026-07-29 | 20:11 ET | [8-K](/filings/0000885590-26-000105.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000885590-26-000105 |
| 2026-07-01 | 20:23 ET | [8-K](/filings/0000885590-26-000089.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000885590-26-000089 |
| 2026-05-19 | 20:18 ET | [8-K](/filings/0000885590-26-000057.md) | 5.07 Shareholder vote results | 0000885590-26-000057 |
| 2026-04-30 | 22:12 ET | [10-Q](/filings/0000885590-26-000053.md) | Quarterly report, period 2026-03-31 | 0000885590-26-000053 |
| 2026-04-29 | 20:10 ET | [8-K](/filings/0000885590-26-000051.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000885590-26-000051 |
| 2026-04-08 | 20:05 ET | [DEF 14A](/filings/0001140361-26-013816.md) | Proxy statement, period 2026-05-19 | 0001140361-26-013816 |
| 2026-03-02 | 22:17 ET | [8-K](/filings/0001193125-26-085755.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-085755 |
| 2026-02-19 | 23:10 ET | [10-K](/filings/0000885590-26-000023.md) | Annual report, period 2025-12-31 | 0000885590-26-000023 |
| 2026-02-18 | 21:12 ET | [8-K](/filings/0000885590-26-000020.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000885590-26-000020 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000885590-26-000023.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c302c9cf-b593-402f-832d-2a4671b8d485)

## About the filer

- CIK: 885590
- Tickers: BHC
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: NJ
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.